Understanding the FDA’s Estrogen Decision and the Evolving Evidence Behind Personalized Hormone Therapy
Join Angela DeRosa, DO, MBA, CPE, Medical Director at Belmar Pharma Solutions, and Andi Roths, PharmD, Director of Women’s Health, as they examine one of the most significant developments in women’s hormonal health in decades: the FDA’s decision to remove the boxed warning from most estrogen products.
Through a review of current clinical literature and practical prescribing considerations, this webinar explores how new evidence is reshaping the conversation around estradiol therapy, menopause management, and individualized hormone replacement. The presenters discuss how evolving research challenges long-held misconceptions about estrogen while reinforcing the importance of personalized therapies that consider each patient’s symptoms, risk factors, and long-term health goals.
What You’ll Learn About Bioidentical Hormones & Estrogen Therapy
Dr. DeRosa and Andi review the scientific evidence that contributed to the FDA’s updated position on estrogen therapy, including studies examining breast cancer risk, cardiovascular disease, venous thromboembolism, and the timing of hormone therapy initiation. They explain the differences between bioidentical estradiol and synthetic estrogen formulations, discuss the role of compounded hormone therapies, and compare the potential benefits of various dosage forms, including:
- Tablets
- Fast-burst sublingual tablets
- Creams
- Vaginal therapies
- Pellets
- Sterile injectables
The webinar also explores clinical considerations for prescribing estradiol during perimenopause and menopause, selecting appropriate formulations, and individualizing therapy to support both symptom management and long-term wellness outcomes.
Applying the Latest Estradiol Evidence to Clinical Practice
Throughout the presentation, Dr. DeRosa and Andi discuss why the conversation around hormone therapy is increasingly extending beyond symptom relief to support cardiovascular, cognitive, skeletal, and overall metabolic health considerations. They also address common misconceptions surrounding estrogen therapy, discuss current educational gaps in menopause care, and reinforce the importance of evidence-based, patient-centered prescribing.
Providers will leave with practical insights for evaluating hormone therapy options, counseling patients with greater confidence, and incorporating the latest clinical evidence into everyday practice.
Whether you’re beginning to prescribe bioidentical hormone replacement therapy (BHRT) or refining an established menopause practice, this webinar provides an evidence-informed overview of the changing landscape of estradiol therapy and women’s hormonal health.
These articles were part of the discussion:
Estrogen and cardiovascular disease
Breast Cancer Prevention: Time for Change
Watch on-demand today.
This webinar is intended for providers. If you are a provider and would like to watch the webinar, please fill out the form below.
